JP2006176498A5 - - Google Patents

Download PDF

Info

Publication number
JP2006176498A5
JP2006176498A5 JP2005335154A JP2005335154A JP2006176498A5 JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5 JP 2005335154 A JP2005335154 A JP 2005335154A JP 2005335154 A JP2005335154 A JP 2005335154A JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hmg
coa reductase
reductase inhibitor
ubidecarenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005335154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006176498A (ja
JP4896501B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2005335154A priority Critical patent/JP4896501B2/ja
Priority claimed from JP2005335154A external-priority patent/JP4896501B2/ja
Publication of JP2006176498A publication Critical patent/JP2006176498A/ja
Publication of JP2006176498A5 publication Critical patent/JP2006176498A5/ja
Application granted granted Critical
Publication of JP4896501B2 publication Critical patent/JP4896501B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2005335154A 2004-11-26 2005-11-21 血中遊離脂肪酸低下作用を有する医薬組成物 Expired - Fee Related JP4896501B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005335154A JP4896501B2 (ja) 2004-11-26 2005-11-21 血中遊離脂肪酸低下作用を有する医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004341493 2004-11-26
JP2004341493 2004-11-26
JP2005335154A JP4896501B2 (ja) 2004-11-26 2005-11-21 血中遊離脂肪酸低下作用を有する医薬組成物

Publications (3)

Publication Number Publication Date
JP2006176498A JP2006176498A (ja) 2006-07-06
JP2006176498A5 true JP2006176498A5 (zh) 2009-01-29
JP4896501B2 JP4896501B2 (ja) 2012-03-14

Family

ID=36730936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005335154A Expired - Fee Related JP4896501B2 (ja) 2004-11-26 2005-11-21 血中遊離脂肪酸低下作用を有する医薬組成物

Country Status (1)

Country Link
JP (1) JP4896501B2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012096998A (ja) * 2009-02-27 2012-05-24 Kowa Co 安定なカプセル製剤及びその製造方法
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2007983C (en) * 1989-01-18 1996-12-10 Michael S. Brown Coenzyme q10 with hmg-coa reductase inhibitors
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
JP2003081873A (ja) * 2001-06-28 2003-03-19 Takeda Chem Ind Ltd 臓器機能障害および臓器不全の予防治療剤
CA2480268A1 (en) * 2002-04-23 2003-11-06 Nutrition 21, Inc. Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance

Similar Documents

Publication Publication Date Title
RU2022100434A (ru) Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения
JP2010047616A5 (zh)
WO2008045170A3 (en) Statin and omega-3 fatty acids for reduction of apo-b levels
JP2015503588A5 (zh)
JP2007523049A5 (zh)
JP2008509132A5 (zh)
JP2004537553A5 (zh)
EA200970359A1 (ru) Статин и омега-3 жирные кислоты для снижения уровней аро-в
JP2007238598A5 (zh)
AR076835A1 (es) Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de drogas en dosis elevadas y reducidas. metodo.
NZ600720A (en) A Seamless Capsule For A Liquid Pharmaceutical Composition
NZ603207A (en) Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
JP2007277267A5 (zh)
AR081032A1 (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
JP2008515980A5 (zh)
NO20065152L (no) Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
JP2005511619A5 (zh)
JP2006176498A5 (zh)
JP2013536408A5 (zh)
JP2010505866A5 (zh)
JP2008063322A5 (zh)
EP2780002A1 (en) Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability
RU2007148908A (ru) Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
JP2005522490A5 (zh)